Objective. Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular
inflammatory mediator synthesis by elevating cyclic adenosine monophosphate levels. The …

Objective. To evaluate the efficacy and safety of apremilast, an oral phosphodiesterase 4
inhibitor, over 52 weeks in patients with active psoriatic arthritis (PsA) despite prior …

Objective To evaluate the efficacy and safety of apremilast, a novel, orally available small
molecule that specifically targets phosphodiesterase 4, in the treatment of active psoriatic …

Apremilast (Otezla®) is an orally administered, small molecule inhibitor of
phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate …

Apremilast (Otezla®) is an oral phosphodiesterase 4 inhibitor indicated for the twice-daily
treatment of adults with psoriasis and psoriatic arthritis (PsA). Its use in these patient …

Objectives Apremilast, an oral phosphodiesterase 4 inhibitor, regulates inflammatory
mediators. Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) …

Objective To evaluate apremilast treatment in patients with active psoriatic arthritis, including
current skin involvement, despite prior therapy with conventional disease-modifying …

Background The efficacy and safety of apremilast were assessed in patients with psoriatic
arthritis (PsA) in three phase III clinical trials with similar designs (PALACE 1, 2, and 3) …

Background Randomized, controlled trials demonstrated efficacy and safety of apremilast for
moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term …

Objective Evaluate apremilast efficacy across various psoriatic arthritis (PsA) manifestations
beginning at week 2 in biological-naïve patients with PsA. Methods Patients were …